Insights+: The US FDA New Drug Approvals in December 2022

Shots: The US FDA approved 8 NDAs and 5 BLA in December 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 86 novel products in 2022 In December 2022, the major highlights drugs were Krazati (adagrasib) approval for non-small cell lung cancer with a KRASG12C mutation, Sunlenca…

BySenior EditorJanuary 18, 2023

INSIGHTS+

J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Amgen (Part 02)

Shots: In the year 2022, Amgen was the top dealmaker, based on the total deal value, with 6 deals at a total announced value of ~$34.5B. Amgen has disclosed 5 out of the 6 deals leaving its BigHat Biosciences deal undisclosed Amgen’s acquisition of Horizon Therapeutics for a value of ~$28.3B was the key contributor…

BySenior EditorJanuary 16, 2023

EVENTS

31st Pharmacovigilance 2023: Catalyzing Pharmacovigilance, Drug Safety and Risk Management.

Virtue Insight is glad to invite you to attend the 31st Pharmacovigilance 2023 which is happening on 01-02 February 2023 at Radisson RED London Heathrow, UK. The focus will be on the latest developments in pharmacovigilance, drug safety & risk management. With the increasing number of diseases and the non-medical use of prescription drugs, the…

BySenior EditorJanuary 13, 2023

INSIGHTS+

Disease of the Month: Cervical Cancer

“Get Informed, Get Screened, Get Vaccinated” – WHO Introduction: Cervical cancer is the 4th most common cancer among women and 7th most commonly occurring cancer overall. When a malignant growth or tumor occurs in the cells lining the walls of the cervix, it is called cervical cancer. The cervix is the narrow, lower part of the uterus…

BySenior EditorJanuary 12, 2023

VIEWPOINTS

Dr. Richard Philipson, CMO at Calliditas Shares Results & Insights from P-III Study Evaluating Tarpeyo

Shots: Dr. Richard talked about the results from the NefIgArd P-III trial evaluating Tarpeyo (Nefecon) for the treatment of IgA Nephropathy He also highlighted the safety and efficacy results from the NefIgArd study. He also spoke more about Trapeyo and the roadmap for its global approval and commercialization The interview shows up how Calliditas is…

BySenior EditorJanuary 9, 2023

INSIGHTS+

J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Roche (Part 01)

Shots: Roche was the top dealmaker in 2022 with a completion of 31 deals with multiple pharma, biotech companies, and universities for a total deal value of $13.55B The highest deal was secured by Roche under its development and commercialization collaboration with Poseida for the R&D of multiple existing and novel cell therapies for the…

BySenior EditorJanuary 5, 2023

INSIGHTS+

Insights+ Key Biosimilars Events of December 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of December, Alvotech and STADA launched Hukyndra (biosimilar, adalimumab)…

BySenior EditorJanuary 4, 2023

VIEWPOINTS

Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

Shots: Jeff spoke about the first patient enrolled in a P-II study of D-4517.2 for the treatment of wet AMD and DME Jeff also talked about Ashvatta’s Hydroxyl Dendrimer Platform and how this technology is beneficial to treat AMD and DME The interview gives a profound understanding of how Ashvattha is developing hydroxyl dendrimer therapeutics…

BySenior EditorJanuary 3, 2023

INSIGHTS+

PharmaShots’ Most Read News of 2022

The year 2022 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements, clinical trial results and gaining approvals. Our team has compiled a list of 30 most read life sciences news on PharmaShots in 2022 1. AVEO Entered into a Clinical Trial Collaboration with Merck KGaA to…

BySenior EditorJanuary 2, 2023

EVENTS

Need Coverage of 41st Annual J.P. Morgan Healthcare Conference 2023?

Need Coverage of 41st Annual J.P. Morgan Healthcare Conference 2023? Shots: The 41st Annual J.P. Morgan Healthcare Conference (JPM 2023) will take place from January 9th to 12th, 2023, in San Francisco, US. It will gather thousands of global investors, emerging companies, innovative technology creators, and members of the investment community With hundreds of presentations lined up…

BySenior EditorDecember 30, 2022

Senior Editor

Insights+: The US FDA New Drug Approvals in December 2022

J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Amgen (Part 02)

31st Pharmacovigilance 2023: Catalyzing Pharmacovigilance, Drug Safety and Risk Management.

Disease of the Month: Cervical Cancer

Dr. Richard Philipson, CMO at Calliditas Shares Results & Insights from P-III Study Evaluating Tarpeyo

J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Roche (Part 01)

Insights+ Key Biosimilars Events of December 2022

Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

PharmaShots’ Most Read News of 2022

Need Coverage of 41st Annual J.P. Morgan Healthcare Conference 2023?

Contact US

OUR INFORMATION

FOLLOW US